{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lieu CH"],"funding":["Division of Cancer Prevention, National Cancer Institute (DCP, NCI)","Division of Cancer Prevention, National Cancer Institute"],"pagination":["1771-1778"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12498271"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(10)"],"pubmed_abstract":["<h4>Purpose</h4>The pathogenesis of colorectal cancer is largely driven by mutations of the tumor suppressor gene APC (adenomatous polyposis coli) that lead to aberrant activation of the β-catenin-dependent (canonical) Wnt signaling pathway. We evaluated basroparib, a tankyrase-selective inhibitor targeting the Wnt/β-catenin signaling pathway, in a first-in-human phase I clinical study for safety, tolerability, pharmacokinetics, and efficacy in patients with advance-stage solid tumors.<h4>Patients and methods</h4>Patients enrolled to this open-label, multicenter study (NCT04505839) were treated with basroparib capsules orally once daily in 28-day cycles (21-day on and 7-day off) in dose escalation at seven dose levels (30-360 mg) following the classic \"3 + 3\" design.<h4>Results</h4>Twenty-"],"journal":["Cancer research communications"],"pubmed_title":["A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors."],"pmcid":["PMC12498271"],"funding_grant_id":["2P30CA046934-34"],"pubmed_authors":["Kim UI","Lieu CH","Kim SH","Lenz HJ","Kim K","Sung MJ","Benson AB","Meng X"],"additional_accession":[]},"is_claimable":false,"name":"A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors.","description":"<h4>Purpose</h4>The pathogenesis of colorectal cancer is largely driven by mutations of the tumor suppressor gene APC (adenomatous polyposis coli) that lead to aberrant activation of the β-catenin-dependent (canonical) Wnt signaling pathway. We evaluated basroparib, a tankyrase-selective inhibitor targeting the Wnt/β-catenin signaling pathway, in a first-in-human phase I clinical study for safety, tolerability, pharmacokinetics, and efficacy in patients with advance-stage solid tumors.<h4>Patients and methods</h4>Patients enrolled to this open-label, multicenter study (NCT04505839) were treated with basroparib capsules orally once daily in 28-day cycles (21-day on and 7-day off) in dose escalation at seven dose levels (30-360 mg) following the classic \"3 + 3\" design.<h4>Results</h4>Twenty-","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T05:44:01.722Z","creation":"2026-05-05T03:13:09.515Z"},"accession":"S-EPMC12498271","cross_references":{"pubmed":["40964966"],"doi":["10.1158/2767-9764.CRC-25-0502"]}}